Keynote-522: Neoadjuvant Pembro + Chemo Vs Placebo + Chemo, Followed By Adjuvant Pembro Vs Place...

KEYNOTE-522: Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs place...

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-...

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBC

KEYNOTE-522: pembro + CT vs placebo + CT neoadjuvant followed adjuvant pembro vs placebo in TNBC

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

KEYNOTE-522: EFS sensitivity & subgroup analyses

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."

San Antonio Breast Cancer Symposium

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

Update on Keynote 522, the current standard of care for triple negative breast cancer.

OncBrothers: Practice-Changing Cancer Discussions

Overall Survival with Pembrolizumab in Breast Cancer | NEJM

Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer Highlights

OncBrothers: Practice-Changing Cancer Discussions

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 study

KEYTRUDA Phase 3 KEYNOTE-522 Trial Data

HPR